Use of perlecan domain V in treating amyloidogenic disease
Abstract
The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of Aβ peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.
Subject
A61K 38/39Collections
Citation
Bix, Gregory J.; Wright, Sarah; Griswold-prenner, Irene (2016). Use of perlecan domain V in treating amyloidogenic disease. United States. Patent and Trademark Office; Texas A&M University. Libraries. Available electronically from http : / /hdl .handle .net /1969 .1 /177150.